These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 28419449)

  • 21. CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer.
    Skiles JL; Chiang C; Li CH; Martin S; Smith EL; Olbara G; Jones DR; Vik TA; Mostert S; Abbink F; Kaspers GJ; Li L; Njuguna F; Sajdyk TJ; Renbarger JL
    Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29115708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia.
    Aplenc R; Glatfelter W; Han P; Rappaport E; La M; Cnaan A; Blackwood MA; Lange B; Rebbeck T
    Br J Haematol; 2003 Jul; 122(2):240-4. PubMed ID: 12846892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.
    Bertaina A; Vinti L; Strocchio L; Gaspari S; Caruso R; Algeri M; Coletti V; Gurnari C; Romano M; Cefalo MG; Girardi K; Trevisan V; Bertaina V; Merli P; Locatelli F
    Br J Haematol; 2017 Feb; 176(4):629-636. PubMed ID: 28116786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies.
    Kamaluddin M; McNally P; Breatnach F; O'Marcaigh A; Webb D; O'Dell E; Scanlon P; Butler K; O'Meara A
    Acta Paediatr; 2001 Oct; 90(10):1204-7. PubMed ID: 11697438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia.
    Kaspers GJL; Niewerth D; Wilhelm BAJ; Scholte-van Houtem P; Lopez-Yurda M; Berkhof J; Cloos J; de Haas V; Mathôt RA; Attarbaschi A; Baruchel A; de Bont ES; Fagioli F; Rössig C; Klingebiel T; De Moerloose B; Nelken B; Palumbo G; Reinhardt D; Rohrlich PS; Simon P; von Stackelberg A; Zwaan CM
    Br J Haematol; 2018 May; 181(4):523-527. PubMed ID: 29676440
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mild axonal neuropathy of children during treatment for acute lymphoblastic leukaemia.
    Reinders-Messelink HA; Van Weerden TW; Fock JM; Gidding CE; Vingerhoets HM; Schoemaker MM; Göeken LN; Bökkerink JP; Kamps WA
    Eur J Paediatr Neurol; 2000; 4(5):225-33. PubMed ID: 11030069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Second neoplasm in children treated in EORTC 58881 trial for acute lymphoblastic malignancies: low incidence of CNS tumours.
    Renard M; Suciu S; Bertrand Y; Uyttebroeck A; Ferster A; van der Werff Ten Bosch J; Mazingue F; Plouvier E; Robert A; Boutard P; Millot F; Munzer M; Mechinaud F; Lescoeur B; Baila L; Vandecruys E; Benoit Y; Philippet P;
    Pediatr Blood Cancer; 2011 Jul; 57(1):119-25. PubMed ID: 21412967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute and sub-acute neurological toxicity in children treated for acute lymphoblastic leukemia.
    Millan NC; Pastrana A; Guitter MR; Zubizarreta PA; Monges MS; Felice MS
    Leuk Res; 2018 Feb; 65():86-93. PubMed ID: 29328996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Severe life threatening neurotoxicity in a child with acute lymphoblastic leukemia receiving posaconazole and vincristine.
    Jain S; Kapoor G
    Pediatr Blood Cancer; 2010 May; 54(5):783. PubMed ID: 20205256
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacogenomics in pediatric acute lymphoblastic leukemia: promises and limitations.
    Al-Mahayri ZN; Patrinos GP; Ali BR
    Pharmacogenomics; 2017 May; 18(7):687-699. PubMed ID: 28468529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In interaction with gender a common CYP3A4 polymorphism may influence the survival rate of chemotherapy for childhood acute lymphoblastic leukemia.
    Gézsi A; Lautner-Csorba O; Erdélyi DJ; Hullám G; Antal P; Semsei ÁF; Kutszegi N; Hegyi M; Csordás K; Kovács G; Szalai C
    Pharmacogenomics J; 2015 Jun; 15(3):241-7. PubMed ID: 25266680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic impact of gained chromosomes in high-hyperdiploid childhood acute lymphoblastic leukaemia: a collaborative retrospective study of the Tokyo Children's Cancer Study Group and Japan Association of Childhood Leukaemia Study.
    Kato M; Imamura T; Manabe A; Hashii Y; Koh K; Sato A; Takahashi H; Hori H; Taki T; Inoue M; Hayashi Y; Horibe K; Tsuchida M; Kojima S; Oda M; Ohara A
    Br J Haematol; 2014 Jul; 166(2):295-8. PubMed ID: 24628674
    [No Abstract]   [Full Text] [Related]  

  • 33. Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity.
    Guilhaumou R; Solas C; Bourgarel-Rey V; Quaranta S; Rome A; Simon N; Lacarelle B; Andre N
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1633-8. PubMed ID: 21968951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia.
    van Schie RM; Brüggemann RJ; Hoogerbrugge PM; te Loo DM
    J Antimicrob Chemother; 2011 Aug; 66(8):1853-6. PubMed ID: 21652620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003.
    Hough R; Rowntree C; Goulden N; Mitchell C; Moorman A; Wade R; Vora A
    Br J Haematol; 2016 Feb; 172(3):439-51. PubMed ID: 26683485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia.
    Gustafsson B; Angelini S; Sander B; Christensson B; Hemminki K; Kumar R
    Leukemia; 2005 Feb; 19(2):310-2. PubMed ID: 15538400
    [No Abstract]   [Full Text] [Related]  

  • 37. Out come of induction of remission in undernourished children with acute lymphoblastic leukaemia.
    Begum M; Jahan S; Tawfique M; Mannan MA
    Mymensingh Med J; 2012 Oct; 21(4):691-5. PubMed ID: 23134919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Analysis of therapy results and prognostic factors in children with acute lymphoblastic leukaemia in Warmia and Mazury region: 17-years experience].
    Badowska W
    Med Wieku Rozwoj; 2008; 12(4 Pt 2):1001-7. PubMed ID: 19531816
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study.
    Balduzzi A; Valsecchi MG; Uderzo C; De Lorenzo P; Klingebiel T; Peters C; Stary J; Felice MS; Magyarosy E; Conter V; Reiter A; Messina C; Gadner H; Schrappe M
    Lancet; 2005 Aug 20-26; 366(9486):635-42. PubMed ID: 16112299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of some rare haplotypes and genotype combinations in the MDR1 gene with childhood acute lymphoblastic leukaemia.
    Semsei AF; Erdélyi DJ; Ungvári I; Kámory E; Csókay B; Andrikovics H; Tordai A; Cságoly E; Falus A; Kovács GT; Szalai C
    Leuk Res; 2008 Aug; 32(8):1214-20. PubMed ID: 18243305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.